Literature DB >> 7293114

A new preparation of modified immune serum globulin (human) suitable for intravenous administration. I. Standardization of the reduction and alkylation reaction.

D D Schroeder, D L Tankersley, J L Lundblad.   

Abstract

Immune serum globulin (ISG) prepared by Cohn cold alcohol fractionation of pooled human plasma was reduced with dithiothreitol (DTT) and alkylated with iodoacetamide and other alkylating agents. Our results show that there are a few labile interheavy chain disulfide bonds in ISG which react rapidly under mild, nondissociating conditions. The extent of disulfide cleavage is controlled primarily by the ratio of DTT to ISG until about 4-5 disulfide bonds have been reduced. We report detailed studies on the variables of ISG concentration, DTT to ISG ratio, pH, and time, leading to a chemically modified ISG that has a controlled and limited number of reduced and alkylated disulfide bonds.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7293114     DOI: 10.1111/j.1423-0410.1981.tb00725.x

Source DB:  PubMed          Journal:  Vox Sang        ISSN: 0042-9007            Impact factor:   2.144


  7 in total

1.  The metabolism and kinetics of 125I-labeled human intravenous IgG preparation (C-425) in rats and rabbits. I. Blood clearance, excretion into urine and feces, and brain uptake.

Authors:  Y Kobayashi; N Kobayashi; T Minaga; M Aihara; A Shigematsu
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1989 Jan-Mar       Impact factor: 2.441

2.  Decreased protective efficacy of reduced and alkylated human immune serum globulin in experimental infection with Haemophilus influenzae type b.

Authors:  J R Schreiber; V A Barrus; G R Siber
Journal:  Infect Immun       Date:  1985-01       Impact factor: 3.441

3.  Safety and tolerability of increased rate of infusion of intravenous immunoglobulin G, 10% in antibody-deficient patients.

Authors:  Erwin W Gelfand; Kim Hanna
Journal:  J Clin Immunol       Date:  2006-05-31       Impact factor: 8.542

4.  Fibronectin enhances the opsonic and protective activity of monoclonal and polyclonal antibody against group B streptococci.

Authors:  H R Hill; A O Shigeoka; N H Augustine; D Pritchard; J L Lundblad; R S Schwartz
Journal:  J Exp Med       Date:  1984-06-01       Impact factor: 14.307

Review 5.  Methods to Design and Synthesize Antibody-Drug Conjugates (ADCs).

Authors:  Houzong Yao; Feng Jiang; Aiping Lu; Ge Zhang
Journal:  Int J Mol Sci       Date:  2016-02-02       Impact factor: 5.923

Review 6.  Antibody-Drug Conjugates for Cancer Therapy: Chemistry to Clinical Implications.

Authors:  Nirnoy Dan; Saini Setua; Vivek K Kashyap; Sheema Khan; Meena Jaggi; Murali M Yallapu; Subhash C Chauhan
Journal:  Pharmaceuticals (Basel)       Date:  2018-04-09

Review 7.  Intravenous immunoglobulins: evolution of commercial IVIG preparations.

Authors:  John A Hooper
Journal:  Immunol Allergy Clin North Am       Date:  2008-11       Impact factor: 3.479

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.